CClinicalTrials.gg
CompletedNCT06312904Updated Feb 5, 2025

Paravertebral Block for Postoperative Analgesia in Children Undergoing Lateral Incision Cardiac Surgery With CBP

An interventional study of paravertebral block and Local infiltration anesthesia in Postoperative Pain, sponsored by Chinese Academy of Medical Sciences, Fuwai Hospital. Completed at 1 site in China. Open to participants aged 6 Years to 14 Years. Per ClinicalTrials.gov, last updated 2025-02-05.

Sponsored by Chinese Academy of Medical Sciences, Fuwai Hospital · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
6 Years to 14 Years
Sex
All
01

Study summary

This study aims to compare the effect of paravertebral block and local infiltration anesthesia on postoperative analgesia in children undergoing lateral incision cardiac surgery with cardiopulmonary bypass. The researchers hope to investigate whether children who undergo paravertebral block experience less postoperative pain, have fewer postoperative complications, and recover more quickly.

02

Conditions studied

  • Postoperative Pain

Browse trials for

Keywords

  • Postoperative analgesia
  • paravertebral block
  • pediatric cardiac surgery
  • enhanced recovery after surgery
03

In context

Pain, Postoperative

5,093 studies on the registry are indexed under Pain, Postoperative; 1,140 are open to participants now.

This study's enrollment of 100 is above the median of 75 across 4,344 interventional studies indexed under Pain, Postoperative.

Browse Pain, Postoperative studies →

Lead sponsor

Chinese Academy of Medical Sciences, Fuwai Hospital is the lead sponsor of 141 studies on the registry; 48 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
6 Years to 14 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  1. Children aged 6-14 years old;
  2. Children who have atrial septal defect or ventricular septal defect scheduled for lateral incision cardiac surgery with cardiopulmonary bypass;
  3. Inform consent signed by the parent or legal guardian.

Exclusion criteria

Exclusion Criteria:

  1. Patients who were intubated, on mechanical circulatory support, or with intravenous inotropes before surgery;
  2. Emergency surgery or redo cardiac surgery;
  3. Body weight more than 50kg;
  4. Diagnosed as severe pulmonary hypertension;
  5. Left ventricular ejection fraction less than 45% in most recent echocardiography before surgery;
  6. Allergic to ropivacaine or other regular anesthetics, analgesics or other medications regularly used in the study;
  7. Preoperative platelet counts less than 100*109/L, coagulopathy or bleeding tendency ;
  8. Preoperatively using antiplatelets or anticoagulants;
  9. Diagnosed with scoliosis or other contraindications for PVB.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
100 participants (actual)

Study arms

  • Experimental
    paravertebral block group

    This group of patients will undergo postoperative paravertebral block.

    Procedure: paravertebral block

  • Active comparator
    local infiltration group

    This group of patients will undergo postoperative local infiltration anesthesia.

    Procedure: Local infiltration anesthesia

Interventions

  • Procedureparavertebral block

    After cardiac surgery, the anesthesiologist will use 3mg/kg of 0.375% ropivacaine to conduct paravertebral block.

  • ProcedureLocal infiltration anesthesia

    After cardiac surgery, the anesthesiologist will use 3mg/kg of 0.375% ropivacaine to conduct local infiltration anesthesia.

06

What researchers measure

Primary outcomes

  1. opioid consumption during the first 24h after surgery

    the total amount of sufentanil and other opioids will be calculated as morphine equivalent dose (MED) divided by body weight

    Time frame: 24 hours postoperatively

Secondary outcomes

  1. FPS-R scale recorded at 6, 12, 18 and 24h postoperatively

    The Faces Pain Scale-Revised (FPS-R) is a self-report measure of pain intensity developed for children. It was adapted from the Faces Pain Scale to make it possible to score the sensation of pain on the widely accepted 0-to-10 metric. The scale shows a close linear relationship with visual analog pain scales across the age range of 4-16 years. The bedside nurse will show the patients a picture of six faces, and score 0, 2, 4, 6, 8, and 10 from left to right. "0" equals "no pain" and "10" equals "very much pain." They will ask the patient to choose a face that represents their current pain condition and record the pain score.

    Time frame: 24 hours postoperatively

  2. The rate of opioid treatment for remedial analgesia between groups

    Time frame: 24 hours postoperatively

Other outcomes

  1. Length of postoperative mechanical ventilation

    Time frame: through study completion, an average of 2 weeks

  2. Length of ICU/hospital stay

    Time frame: through study completion, an average of 2 weeks

  3. The incidence of respiratory depression

    The respiratory depression is defined as: with no obvious upper respiratory tract obstruction: SpO2 \< 90% and lasts for more than one minute, or respiratory rate \< 8 times/min, or SpO2 \< 94% and respiratory rate \< 10 times/min, or supplemental oxygen is needed to maintain SpO2 \> 94%.

    Time frame: through study completion, an average of 2 weeks

  4. The rate of postoperative nausea and vomiting (PONV) during the 24h postoperatively

    Time frame: through study completion, an average of 2 weeks

07

Study locations

1 site
  • Fuwai Hospital, National Center for Cardiovascular Diseases
    Beijing, China
08

References and documents

Study documents

  • Protocol, analysis plan and consent form · Feb 26, 2024

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: Yes — The original data will be published in 2025 on http://www.medresman.org.cn

Supporting information: Study protocol, Sap, Icf, Csr, Analytic code

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 5, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06312904
Lead sponsor
Chinese Academy of Medical Sciences, Fuwai Hospital
Responsible party
Jingfei Guo (Attending Physician, Department of Anesthesiology, Chinese Academy of Medical Sciences, Fuwai Hospital) — Principal investigator
First posted
Mar 15, 2024
Start date
Mar 11, 2024
Primary completion
Aug 9, 2024
Completion
Aug 14, 2024
Last update
Feb 5, 2025

Study contacts

Jingfei Guo
study chair · Fuwai Hospital, National Center for Cardiovascular Diseases

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion